Lasmiditan

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Lasmiditan
Accession Number
DB11732
Type
Small Molecule
Groups
Investigational
Description

Lasmiditan has been used in trials studying the basic science and treatment of Migraine, Pharmacokinetics, Migraine Disorders, and Bioavailability Under Fed and Fasted Conditions.

Structure
Thumb
Synonyms
Not Available
External IDs
COL-144
Categories
UNII
760I9WM792
CAS number
439239-90-4
Weight
Average: 377.367
Monoisotopic: 377.135111321
Chemical Formula
C19H18F3N3O2
InChI Key
XEDHVZKDSYZQBF-UHFFFAOYSA-N
InChI
InChI=1S/C19H18F3N3O2/c1-25-7-5-11(6-8-25)18(26)15-3-2-4-16(23-15)24-19(27)17-13(21)9-12(20)10-14(17)22/h2-4,9-11H,5-8H2,1H3,(H,23,24,27)
IUPAC Name
2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)pyridin-2-yl]benzamide
SMILES
CN1CCC(CC1)C(=O)C1=CC=CC(NC(=O)C2=C(F)C=C(F)C=C2F)=N1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of adverse effects can be increased when Lasmiditan is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of adverse effects can be increased when Lasmiditan is combined with (S)-Warfarin.
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of serotonin syndrome can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Lasmiditan.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Lasmiditan is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Lasmiditan.
4-hydroxycoumarinThe risk or severity of adverse effects can be increased when Lasmiditan is combined with 4-hydroxycoumarin.
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Lasmiditan.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Lasmiditan is combined with 5-methoxy-N,N-dimethyltryptamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Lasmiditan.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Lasmiditan.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
11610526
PubChem Substance
347828091
ChemSpider
9785281
ChEMBL
CHEMBL3039520
Wikipedia
Lasmiditan

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceAcute Treatment of Migraine / Migraine1
1CompletedBasic ScienceBioavailability Under Fed and Fasted Conditions / Healthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers9
1CompletedBasic ScienceMigraine2
1CompletedBasic ScienceMigraine Disorders1
1CompletedBasic SciencePrescription Drug Abuse (Not Dependent) / Recreational Drug Use1
1CompletedOtherMigraine1
1Not Yet RecruitingBasic ScienceMigraine1
1Not Yet RecruitingTreatmentHealthy Volunteers1
2CompletedTreatmentMigraine1
2CompletedTreatmentMigraine Disorders1
2RecruitingTreatmentMigraine1
3Active Not RecruitingTreatmentAcute Treatment of Migraine in Adults / Migraine Disorders1
3CompletedTreatmentAcute Migraine1
3CompletedTreatmentAcute Migraine / Migraine With or Without Aura1
3RecruitingTreatmentMigraine1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0175 mg/mLALOGPS
logP2.76ALOGPS
logP3.1ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)9.35ChemAxon
pKa (Strongest Basic)7.97ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area62.3 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity96.15 m3·mol-1ChemAxon
Polarizability35.61 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 4-halobenzoic acids and derivatives. These are benzoic acids or derivatives carrying a halogen atom at the 4-position of the benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
4-halobenzoic acids and derivatives
Alternative Parents
2-halobenzoic acids and derivatives / Benzamides / Aryl alkyl ketones / Benzoyl derivatives / Fluorobenzenes / Aryl fluorides / Pyridines and derivatives / Piperidines / Gamma-amino ketones / Imidolactams
show 10 more
Substituents
2-halobenzoic acid or derivatives / 4-halobenzoic acid or derivatives / Benzamide / Benzoyl / Aryl ketone / Aryl alkyl ketone / Fluorobenzene / Halobenzene / Aryl fluoride / Aryl halide
show 26 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 14:43 / Updated on June 04, 2019 07:26